Zev A. Wainberg, MD

Zev A. Wainberg, MD, is a professor of medicine at the University of California, Los Angeles (UCLA) and co-director of the UCLA GI Oncology Program.

Articles by Zev A. Wainberg, MD

Drs Yelena Janjigian and Zev Wainberg | Background image credit: ipopba - stock.adobe.com

Experts Say FDA Approval of Perioperative Durvalumab Plus FLOT Sets New Standard of Care for Early-Stage Gastric, GEJ Cancers

ByBrooke McCormick,Yelena Y. Janjigian, MD,Zev A. Wainberg, MD

December 3rd 2025

As the first immunotherapy option in this setting, the approval sets a new standard for resectable early-stage gastric and gastroesophageal junction (GEJ) cancers.

Zev A. Wainberg, MD

Articles by Zev A. Wainberg, MD

Experts Say FDA Approval of Perioperative Durvalumab Plus FLOT Sets New Standard of Care for Early-Stage Gastric, GEJ Cancers

Latest Updated Articles

Trending on AJMC

Flatiron’s AI-Driven Telescope Makes Data Access More User-Friendly

Social Factors May Match, Outpace Genetic Risk in Disease Prediction

First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention

Long-Term, Consistent Resistance Training Linked to Substantially Lower Type 2 Diabetes Risk

Mixed Phase 3 Results for IB6-Targeting ADC Raise Questions on Optimal Use in NSCLC

Access, Affordability, & Accountability: A New Era in Oncology Reimbursement

Zev A. Wainberg, MD

Articles by Zev A. Wainberg, MD

Experts Say FDA Approval of Perioperative Durvalumab Plus FLOT Sets New Standard of Care for Early-Stage Gastric, GEJ Cancers

Latest Updated Articles

Trending on AJMC

Flatiron’s AI-Driven Telescope Makes Data Access More User-Friendly

Social Factors May Match, Outpace Genetic Risk in Disease Prediction

First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention

Long-Term, Consistent Resistance Training Linked to Substantially Lower Type 2 Diabetes Risk

Mixed Phase 3 Results for IB6-Targeting ADC Raise Questions on Optimal Use in NSCLC